Home › Compare › SPAN vs MRK

SPAN vs MRK: Dividend Comparison 2026

SPAN yields 6.67% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPAN wins by $335.00 in total portfolio value
10 years
SPAN
SPAN
● Live price
6.67%
Share price
$29.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.1K
Annual income
$1,019.09
Full SPAN calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — SPAN vs MRK

📍 SPAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPANMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPAN + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SPAN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPAN
Annual income on $10K today (after 15% tax)
$566.86/yr
After 10yr DRIP, annual income (after tax)
$866.23/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, SPAN beats the other by $58.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPAN + MRK for your $10,000?

SPAN: 50%MRK: 50%
100% MRK50/50100% SPAN
Portfolio after 10yr
$30.9K
Annual income
$984.70/yr
Blended yield
3.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SPAN
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPAN buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPANMRK
Forward yield6.67% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$31.1K ✓$30.7K
Annual income after 10y$1,019.09 ✓$950.29
Total dividends collected$8.5K ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPAN vs MRK ($10,000, DRIP)

YearSPAN PortfolioSPAN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,367$666.89$11,192$351.54+$175.00 → SPAN
2$12,871$708.45$12,524$392.70+$347.00 → SPAN
3$14,522$749.72$14,015$438.65+$507.00 → SPAN
4$16,329$790.53$15,682$489.96+$647.00 → SPAN
5$18,303$830.75$17,547$547.23+$756.00 → SPAN
6$20,454$870.25$19,632$611.16+$822.00 → SPAN
7$22,795$908.93$21,963$682.53+$832.00 → SPAN
8$25,337$946.67$24,571$762.18+$766.00 → SPAN
9$28,094$983.42$27,486$851.08+$608.00 → SPAN
10$31,080$1,019.09$30,745$950.29+$335.00 → SPAN

SPAN vs MRK: Complete Analysis 2026

SPAN — Stock

SPAN is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in SPAN shares.

Full SPAN Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this SPAN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPAN vs SCHDSPAN vs JEPISPAN vs OSPAN vs KOSPAN vs MAINSPAN vs JNJSPAN vs ABBVSPAN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.